VivoSeq
Other

Sudden Sensorineural Hearing Loss

12

Pipeline Programs↗

7

Active Trials↗

10

Companies Involved↗

Sudden Sensorineural Hearing Loss is an emerging landscape with 12 programs across 10 companies. The most active players are AstraZeneca, AudioCure Pharma GmbH, Alnylam Pharmaceuticals. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

25/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1A

AudioCure Pharma GmbH

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2S

Sensorion

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

14

clinical trials

Not yet recruiting4 · 29%
Unknown status3 · 21%
Terminated2 · 14%
Active, not recruiting2 · 14%
Withdrawn1 · 7%
Completed1 · 7%
Other1 · 7%

Clinical Trials

Trial Activity

14 trials

Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss
Recruiting·—·Phase 4·NCT06968507·214 enrolled
Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)
Active, not recruiting·AAudioCure Pharma GmbH·Phase 2·NCT05776459·210 enrolled
Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss
Active, not recruiting·ZZhongshan Hospital Xiamen University·N/A·NCT07045883·197 enrolled
Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss
Not yet recruiting·—·Phase 4·NCT06878599·70 enrolled
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
Not yet recruiting·—·Phase 2·NCT06467526·80 enrolled
Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT07113158·142 enrolled
Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss
Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1/2·NCT07404709·9 enrolled
Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Completed·SSensorion·Phase 2/3·NCT03603314·115 enrolled
Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment
Terminated·AAuris Medical AG·Phase 3·NCT02809118·56 enrolled
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss
Terminated·—·Phase 1/2·NCT02414152·2 enrolled
High Dose Oral Steroids in Sudden Sensorineural Hearing Loss
Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT03255473
Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT05849519·36 enrolled
Bed Rest for Idiopathic Sudden Sensorineural Hearing Loss
Unknown status·SSheba Medical Center·Phase 2/3·NCT00416143·60 enrolled
The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
Unknown status·—·Phase 2·NCT05403229·140 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)